PURPOSE: White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect characterized by an intralesional or perilesional reaction. We report the occurrence of subacute WMLs detected by magnetic resonance imaging (MRI) in children treated for medulloblastoma or primitive neuroectodermal tumor (PNET) and document the associated clinical, radiologic, and neurocognitive findings. PATIENTS AND METHODS: Among 134 patients with medulloblastoma or supratentorial PNET treated prospectively with risk-adjusted craniospinal irradiation and conformal boost to the tumor bed, followed by four high-dose chemotherapy (HDC) cycles with stem-cell rescue, 22 developed WMLs on T1-weighted imaging with and without contrast and/or T2-weighted imaging on MRI. Patients had > or = 12 months of follow-up. Neurocognitive assessments included intelligence quotient (IQ) tests and tests of academic achievement. RESULTS: Twenty-two patients developed WMLs at a median of 7.8 months after starting therapy (range, 1.9 to 13.0 months). Lesions were predominantly in the pons (n = 8) and cerebellum (n = 6). Sixteen patients (73%) had WML resolution at a median of 6.2 months (range, 1.68 to 23.5 months) after onset; two patients developed necrosis and atrophy. Three developed persistent neurologic deficits. Cumulative incidence of WMLs at 1 year was 15% +/- 3%. Patients with WMLs had a significant decline in estimated IQ (-2.5 per year; P = .03) and math (-4.5 per year; P = .003) scores. CONCLUSION: WMLs in medulloblastoma or PNET patients treated with conformal radiotherapy and HDC are typically transient and asymptomatic, and may mimic early tumor recurrence. A minority of patients with WMLs develop permanent neurologic deficits and imaging changes. Overall, the presence of WMLs is associated with greater neurocognitive decline.
PURPOSE:White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect characterized by an intralesional or perilesional reaction. We report the occurrence of subacute WMLs detected by magnetic resonance imaging (MRI) in children treated for medulloblastoma or primitive neuroectodermal tumor (PNET) and document the associated clinical, radiologic, and neurocognitive findings. PATIENTS AND METHODS: Among 134 patients with medulloblastoma or supratentorial PNET treated prospectively with risk-adjusted craniospinal irradiation and conformal boost to the tumor bed, followed by four high-dose chemotherapy (HDC) cycles with stem-cell rescue, 22 developed WMLs on T1-weighted imaging with and without contrast and/or T2-weighted imaging on MRI. Patients had > or = 12 months of follow-up. Neurocognitive assessments included intelligence quotient (IQ) tests and tests of academic achievement. RESULTS: Twenty-two patients developed WMLs at a median of 7.8 months after starting therapy (range, 1.9 to 13.0 months). Lesions were predominantly in the pons (n = 8) and cerebellum (n = 6). Sixteen patients (73%) had WML resolution at a median of 6.2 months (range, 1.68 to 23.5 months) after onset; two patients developed necrosis and atrophy. Three developed persistent neurologic deficits. Cumulative incidence of WMLs at 1 year was 15% +/- 3%. Patients with WMLs had a significant decline in estimated IQ (-2.5 per year; P = .03) and math (-4.5 per year; P = .003) scores. CONCLUSION: WMLs in medulloblastoma or PNET patients treated with conformal radiotherapy and HDC are typically transient and asymptomatic, and may mimic early tumor recurrence. A minority of patients with WMLs develop permanent neurologic deficits and imaging changes. Overall, the presence of WMLs is associated with greater neurocognitive decline.
Authors: Ali Mahta; Yan Qu; Denis Nastic; Maria Sundstrom; Ryan Y Kim; Marlon Saria; Sandro Santagata; Santosh Kesari Journal: Pathol Oncol Res Date: 2011-09-28 Impact factor: 3.201
Authors: Susan L McGovern; M Fatih Okcu; Mark F Munsell; Nancy Kumbalasseriyil; David R Grosshans; Mary F McAleer; Murali Chintagumpala; Soumen Khatua; Anita Mahajan Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-11 Impact factor: 7.038
Authors: Or Cohen-Inbar; Patrick Melmer; Cheng-chia Lee; Zhiyuan Xu; David Schlesinger; Jason P Sheehan Journal: J Neurooncol Date: 2016-01 Impact factor: 4.130
Authors: N D Sabin; T E Merchant; J H Harreld; Z Patay; P Klimo; I Qaddoumi; G T Armstrong; K Wright; J Gray; D J Indelicato; A Gajjar Journal: AJNR Am J Neuroradiol Date: 2012-07-19 Impact factor: 3.825
Authors: Lei Shi; M Constance Linville; Elizabeth Iversen; Doris P Molina; Jessie Yester; Kenneth T Wheeler; Michael E Robbins; Judy K Brunso-Bechtold Journal: J Neurol Sci Date: 2009-07-21 Impact factor: 3.181
Authors: V Strenger; H Lackner; R Mayer; P Sminia; P Sovinz; M Mokry; A Pilhatsch; M Benesch; W Schwinger; M Seidel; D Sperl; S Schmidt; C Urban Journal: Strahlenther Onkol Date: 2013-08-22 Impact factor: 3.621